Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Daiichi Sankyo
Pharma
Ono-Deciphera, Novartis-PeptiDream, WuXi Bio—Fierce Pharma Asia
Ono will buy Deciphera for $2.4 billion. Novartis invests further in radiotherapy with two deals. WuXi Biologics has withdrawn from the BIO 2024.
Angus Liu
May 3, 2024 7:20am
AZ, Daiichi tout Enhertu win in earlier, broader HER2-low cancer
Apr 29, 2024 10:38am
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
Apr 26, 2024 5:45am
Geopolitical tensions, Carvykti, Enhertu—Fierce Pharma Asia
Apr 12, 2024 8:20am
AZ, Daiichi's Enhertu cleared by FDA in wide range of tumors
Apr 8, 2024 10:49am
Abzena earmarks $5M to bolster ADC services at Pennsylvania site
Mar 28, 2024 8:40am